bioRxiv Science⌕ Search

Biology subjects

Cassataro, J.

Publications and source records attributed to Cassataro, J..

3 recordsLinked to original sources

SUMO chains depolymerization induces slender to stumpy differentiation in T. brucei bloodstream parasites

Trypanosoma brucei are extracellular protozoan parasites transmitted by tsetse flies that cause sleeping sickness in humans and nagana in cattle. Inside the mammalian host, differentiation from a bloodstream replicative slender form into a quiescent stumpy form allows the persistence of the parasite and the spread of the infection. SUMOylation is a reversible and dynamic post-translational modification of proteins that regulates diverse nuclear processes, such as DNA replication, repair and transcription. SUMO can be attached to its target proteins either as a single monomer or forming polymeric chains. We found that transgenic cell lines able to conjugate SUMO just as a monomer are attenuated in vivo. SUMO chain mutant monomorphic parasites display relapsing and remitting waves of parasitemia, at variance with wild-type parasites that cause unremitting parasitemia and mice death. Furthermore, when mice are infected with an analogous SUMO chain mutant generated in a differentiation-competent pleomorphic background, stumpy cells can be observed at unusually low parasitemia values. Our study reveals that SUMO depolymerization could represent a coordinated signal triggered during a quiescence activation program.

molecular biology↗

A Gamma-adapted recombinant subunit vaccine induces broadly neutralizing antibodies against SARS-CoV-2 variants and protects mice from SARS-CoV-2 infection.

The COVID-19 pandemic continues with the emergence of successive new variants of concern (VOC). One strategy to prevent breakthrough infections is developing safe and effective broad-spectrum vaccines. Here, we present preclinical studies of a RBD recombinant vaccine candidate derived from the Gamma SARS-CoV-2 variant adjuvanted with alum. Gamma RBD-derived antigen elicited better neutralizing antibody and T cell responses than formulation containing ancestral RBD antigen. The Gamma-adapted subunit vaccine elicited a long-lasting antibody response with cross-neutralizing activity against different VOC including the Omicron variant. Additionally, Gamma variant RBD-adapted vaccine elicited robust T cells responses with induction of Th1 and CD8+ T cell responses in spleen and lung. Vaccine-induced immunity protected K18-hACE2 mice from intranasal challenge with SARS-CoV-2 increasing survival, reducing body weight loss and viral burden in the lungs and brain. Importantly, the subunit vaccine demonstrated a potent effect as heterologous booster of different vaccine platforms including the non-replicating adenovirus vaccine ChAdOx1-S, the mRNA vaccine BNT162b2 and the inactivated SARS-CoV-2 vaccine BBIBP-CorV, increasing cross-reactive antibody responses. Our study indicates that the adjuvanted Gamma RBD vaccine is highly immunogenic and a broad-spectrum vaccine candidate to combat SARS-CoV-2 variants including Omicron.

immunology↗

A novel bacterial protease inhibitor adjuvant in RBD-based COVID-19 vaccine formulations increases neutralizing antibodies, specific germinal center B cells and confers protection against SARS-CoV-2 infection.

In this work we evaluated recombinant receptor binding domain (RBD) based vaccine formulation prototypes with potential for further clinical development. We assessed different formulations containing RBD plus Alum, AddaS03, AddaVax or the combination of Alum and U-Omp19: a novel Brucella spp. protease inhibitor vaccine adjuvant. Results show that the vaccine formulation composed of U-Omp19 and Alum as adjuvants have a better performance: it significantly increased mucosal and systemic neutralizing antibodies in comparison to antigen plus Alum, AddaVax or AddaS03. Antibodies induced with the formulation containing U-Omp19 not only increased their neutralization capacity against the wild-type virus but also cross neutralized alpha, lambda and gamma variants with similar potency. Also, addition of U-Omp19 to vaccine formulation increased the frequency of RBD-specific geminal center B cells and plasmablasts. Additionally, U-Omp19+Alum formulation induced RBD-specific Th1 and CD8+ T cell responses in spleens and lungs. Finally, this vaccine formulation conferred protection against an intranasal SARS-CoV-2 challenge of K18-hACE2 mice.

immunology↗